Proton transfer is central to numerous important systems, from biology to energy storage. Probing the details of proton ...

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced participation ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...

We apologize, but this video has failed to load. These additions have been made in preparation for the commencement of Cybin’s Phase 3 pivotal trial of CYB003, its proprietary deuterated psilocin ...

The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is ...

Discover Sun Pharmaceutical's new patent for synthesizing D-serine-2-d, detailing innovative methods and versatile compounds for advanced pharmaceutical applications.

SAL0114, a novel formulation combining deuterated dextromethorphan (in which hydrogen atoms are replaced with deuterium) with bupropion, seeks to enhance dextromethorphan stability through deuteration ...

We have two assets in the clinic at the moment. Our CYB003 program, which is a deuterated psilocin, has completed Phase 2. We have some really spectacular Phase 2 results that I'd be happy to ...

"We are making rapid advancements in our two lead clinical programs – CYB003, our proprietary deuterated psilocin program in development for the adjunctive treatment of Major Depressive Disorder ...

The candidate in question is gildeuretinol acetate, also called ALK-001, a form of deuterated vitamin A assessed in a phase 3 trial dubbed SAGA. The 24-month study enrolled 198 patients with GA ...